Yıl: 2020 Cilt: 44 Sayı: 1 Sayfa Aralığı: 24 - 33 Metin Dili: İngilizce DOI: 10.3906/biy-1907-3 İndeks Tarihi: 30-04-2020

The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death

Öz:
Hepatocellular carcinoma (HCC) is the third main cause of cancer-related death. Cyclin-dependent kinases (CDKs) and theircyclin partners regulate the cell cycle. Since inhibition of CDKs gives some guiding ideas for cancer studies, we aimed to determine thepossible effects of R547, a cyclin kinase 1-2-4 inhibitor, on proliferation and apoptotic mechanisms of Hep G2 cells (human) and H-4-II-E cells derived from rat HCC. We determined in vitro survival rates with MTT assay, apoptosis with flow cytometry, morphologicalchanges with confocal microscopy, and ultrastructural changes by transmission electron microscopy. Cisplatin was used as a positivecontrol. After 24 h of culture with 0.1, 1, 10, 50, and 100 µM doses of R547, the corresponding percentages of live Hep G2 cells were101%, 94%, 93%, 89%, and 79% (P < 0.001), respectively. However, with the same R547 doses the live Hep G2 cell percentages were92%, 101%, 53.6% (P <0 .01), 47.4% (P < 0.001), and 41% (P < 0.001), respectively, after 48 h. After 24 h of incubation with the samedoses of R547, the survival percentages of live rat cells were 90%, 80% (P < 0.01), 63% (P < 0.001), 47% (P < 0.001), and 43% (P < 0.001),respectively. The percentages of surviving H-4-II-E cells were 96%, 85% (P < 0.01), 46% (P < 0.001), 44% (P < 0.001), and 45% (P <0.01), respectively, after 48 h. Since R547 did not significantly affect Hep G2 cell survival in 24 h, experiments of apoptosis were carriedout with H-4-II-E cells. The early apoptotic rates of 38% and 45% (P < 0.05 for both) after applications of 10 and 25 μM R547 (control:4.1%), respectively, indicated that R547 has an apoptotic effect on H-4-II-E cells in 24 h. The apoptosis morphology at 24 h of treatmentwas clearly observed with microscopic examinations. According to our results, it is obvious that R547 has antiproliferative action whencompared to cisplatin.
Anahtar Kelime:

Konular: Biyoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB et al. (2017). Palbociclib (PD-0332991), a selective CDK4 / 6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66 (7): 1286-1296. doi: 10.1136/ gutjnl-2016-312268
  • Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS et al. (2010). Xylocydine, a novel CDK inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer Letters 287 (2): 196-206. doi: 10.1016/j.canlet.2009.06.011
  • De Pinto W, Chu XJ, Xuefeng Y, Smith M, Packman K et al. (2006). In vitro and in vivo activity of R547: A potent and selective cyclindependent kinase inhibitor currently in phase I clinical trials. Cancer Therapy 5 (11): 2644-2658. doi: 10.1158/1535-7163
  • Doonan F, Cotter TG. (2008). Morphological assessment of apoptosis. Methods 44 (3): 200-204. doi: 10.1016/j.ymeth.2007.11.006
  • Funk JO (2005). Cell Cycle Checkpoint Genes and Cancer. Encyclopedia of Life Sciences. New York, NY, USA: John Wiley & Sons, Ltd. doi: 10.1038/npg.els.0006046
  • Kang HW, Muramatsu H, Lee BJ, Kwon YS (2010). Monitoring of anticancer effect of cisplatin and 5-fluorouracil on HepG2 cells by quartz crystal microbalance and micro CCD camera. Biosensors and Bioelectronics 26 (4): 1576-1581. doi: 10.1016/j. bios.2010.07.116
  • Kishimoto S, Yasuda M, Suzuki R, Fukushima S (2016). Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum (II) complex in cisplatin-resistant tumor cells. Biometals 29 (6): 1075-1083. doi: 10.1007/s10534-016-9978-5
  • Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55-63. doi: 10.1016/0022-1759(83)90303-4
  • Oztopcu-Vatan P, Sayitoglu M, Gunindi M, Inan E (2015). Cytotoxic and apoptotic effects of menadione on rat hepatocellular carcinoma cells. Cytotechnology 67 (6): 1003-1009. doi: 10.1007/s10616-014-9739-7
  • Peyressatre M, Prével C, Pellerano M, Morris MC (2015). Targeting cyclin-dependent kinases in human cancers. Cancers 7 (1): 179-237. doi: 10.3390/cancers7010179
  • Sánchez-Martinez C, Gelbert LM, Lallena MJ, Dios A (2015). Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorganic & Medicinal Chemistry Letters 25 (17): 3420-3435. doi: 10.1016/j.bmcl.2015.05.100
  • Shackelford RE, Kaufmann WK, Paules RS (1999). Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environmental Health Perspectives 107 (Suppl. 1): 5-24. doi: 10.1289/ ehp.99107s15
  • Shi XN, Li H, Yao H, Liu X, Li L et al. (2015) In silico identification and in vivo validation of anti-psychotic drugs. PLoS One 10 (7): e0132072. doi: 10.1371/journal.pone.0132072
  • Sorf A, Novotna E, Hofman J, Morell A (2019) Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology 163: 290-298. doi: 10.1016/j.bcp.2019.02.035
  • Wang F, He L, Dai WQ, Xu YP, Wu D et al. (2012). Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One 7 (12): e50638. doi: 10.1371/journal.pone.0050638
  • Xiao J, Qiu P, Lai X, He P, Wu Y et al. (2014). Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxeltreated HepG2 cells. Neoplasma 61 (1): 41-47.
  • Xu MY, Kim YS (2014). Antitumor activity of glycyrol via induction of cell cycle arrest, apoptosis and defective autophagy. Food and Chemical Toxicology 74: 311-319. doi: 10.1016/j. fct.2014.10.023
  • Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB (2012). Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochemical Pharmacology 83 (9): 1278-1289. doi: 10.1016/j. bcp.2012.02.002
  • Zhang JF, Liu JJ, Lu MQ, Cai CJ, Yang Y et al. (2007). Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transplant Immunology 17 (3): 162- 168. doi: 10.1016/j.trim.2006.12.003
APA HACIOĞLU B, KUŞ G, KUTLU H, kabadere s (2020). The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. , 24 - 33. 10.3906/biy-1907-3
Chicago HACIOĞLU Betül,KUŞ Gökhan,KUTLU HATİCE MEHTAP,kabadere selda The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. (2020): 24 - 33. 10.3906/biy-1907-3
MLA HACIOĞLU Betül,KUŞ Gökhan,KUTLU HATİCE MEHTAP,kabadere selda The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. , 2020, ss.24 - 33. 10.3906/biy-1907-3
AMA HACIOĞLU B,KUŞ G,KUTLU H,kabadere s The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. . 2020; 24 - 33. 10.3906/biy-1907-3
Vancouver HACIOĞLU B,KUŞ G,KUTLU H,kabadere s The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. . 2020; 24 - 33. 10.3906/biy-1907-3
IEEE HACIOĞLU B,KUŞ G,KUTLU H,kabadere s "The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death." , ss.24 - 33, 2020. 10.3906/biy-1907-3
ISNAD HACIOĞLU, Betül vd. "The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death". (2020), 24-33. https://doi.org/10.3906/biy-1907-3
APA HACIOĞLU B, KUŞ G, KUTLU H, kabadere s (2020). The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turkish Journal of Biology, 44(1), 24 - 33. 10.3906/biy-1907-3
Chicago HACIOĞLU Betül,KUŞ Gökhan,KUTLU HATİCE MEHTAP,kabadere selda The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turkish Journal of Biology 44, no.1 (2020): 24 - 33. 10.3906/biy-1907-3
MLA HACIOĞLU Betül,KUŞ Gökhan,KUTLU HATİCE MEHTAP,kabadere selda The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turkish Journal of Biology, vol.44, no.1, 2020, ss.24 - 33. 10.3906/biy-1907-3
AMA HACIOĞLU B,KUŞ G,KUTLU H,kabadere s The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turkish Journal of Biology. 2020; 44(1): 24 - 33. 10.3906/biy-1907-3
Vancouver HACIOĞLU B,KUŞ G,KUTLU H,kabadere s The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turkish Journal of Biology. 2020; 44(1): 24 - 33. 10.3906/biy-1907-3
IEEE HACIOĞLU B,KUŞ G,KUTLU H,kabadere s "The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death." Turkish Journal of Biology, 44, ss.24 - 33, 2020. 10.3906/biy-1907-3
ISNAD HACIOĞLU, Betül vd. "The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death". Turkish Journal of Biology 44/1 (2020), 24-33. https://doi.org/10.3906/biy-1907-3